6-Hydroxydopamine hydrobromide
Tocris Bioscience | Catalog # 2547
Key Product Details
Description
Alternative Names
Product Description
6-Hydroxydopamine hydrobromide is a selective catecholaminergic neurotoxin. Depletes brain catecholamine levels via uptake and accumulation by a transport mechanism specific to these neurons. Causes almost complete destruction of nigral dopaminergic neurons and their striatal terminals when injected into the substantia nigra of rats, producing an animal model of Parkinson's disease.
Product Specifications for 6-Hydroxydopamine hydrobromide
Molecular Weight
Formula
Storage
Chemical Name
CAS Number
PubChem ID
InChI Key
SMILES
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 25.01 | 100 | |
| DMSO | 25.01 | 100 |
Preparing Stock Solutions for 6-Hydroxydopamine hydrobromide
The following data is based on the product molecular weight 250.09.
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 4.00 mL | 19.99 mL | 39.99 mL |
| 5 mM | 0.80 mL | 4.00 mL | 8.00 mL |
| 10 mM | 0.40 mL | 2.00 mL | 4.00 mL |
| 50 mM | 0.08 mL | 0.40 mL | 0.80 mL |
Calculators
Background References
References are publications that support the biological activity of the product. See our Citations tab to view 23 publications citing the usage of this product.
- Soto-Otero Autoxidation and neurotoxicity of 6-hydroxyDA in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J.Neurochem. 2000 PMID: 10737618
- Fujita Cell-permeable cAMP analog suppresses 6-hydroxyDA-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 2006 PMID: 16945353
- Breese and Traylor Effect of 6-hydroxyDA on brain NE and DA: evidence for selective degeneration of catecholamine neurons. J.Pharmacol.Exp.Ther. 1970 PMID: 5456173
Product Documents for 6-Hydroxydopamine hydrobromide
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Product Specific Notices for 6-Hydroxydopamine hydrobromide
For research use only
Citations for 6-Hydroxydopamine hydrobromide
Customer Reviews for 6-Hydroxydopamine hydrobromide (2)
Have you used 6-Hydroxydopamine hydrobromide?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Customer Images
-
Species: MouseAssay Type: In VivoCell Line/Tissue: neuronVerified Customer | Posted 06/15/20203-4 mg/ml
-
Species: MouseAssay Type: In VivoVerified Customer | Posted 07/03/2018Although 6-Hydroxydopamine hydrobromide (6-OHDA.HBr #2547) dissolves very well in aqueous solutions, some tips are necessary to guarantee its stability for biological experiments. 1. When calculating the 6-OHDA concentration, take in consideration that the doses that are often reported are for the free base and not for the hydrobromide (HBr) conjugated salt. Thus, in the case of 6-OHDA.HBr (#2547), the presence of HBr has to be taken into account in making the proper solution. HBr has a molecular weight of 80.91 and represents 32.352% of the 6-OHDA.HBr (#2547) molecular mass. 2. Always dissolve the 6-OHDA salt in buffers containing antioxidant capacity. I suggest adding 1 mM ascorbic acid (#4055) into PBS. I know some colleagues that have used sodium metabisulfite as well with great success. 3. Always make fresh solutions. The 6-OHDA solution is extremely prone to oxidation, even when resuspended in antioxidant buffers. When fresh, it looks dark red. However, it turns to brown after a few hours. 4. Finally, 6-OHDA is extremely toxic. Therefore always be cautious when handling it.I used the 6-Hydroxydopamine (6-OHDA) to deplete dopaminergic cells from the mouse brain, which is largely used as an experimental model of Parkinson's Disease. The 6-OHDA was injected into the mouse striatum and 21 days later we observed that the dopaminergic neurons (positive for tyrosine hydroxylase immunofluorescence) were almost absent in the substantia nigra pars compacta (SNc) from the 6-OHDA injected hemisphere (on the left). As a control for analytical comparisons, we also injected PBS into the contralateral hemisphere (on the right). When this neurotoxin is injected into striatum, as in this case, there is only a slight depletion of dopaminergic neurons from the ventral tegmental area (the region located into the middle of the image). The animals injected with 6-OHDA display several motor dysfunctions and are used to study the pathology and therapies for Parkinsonian symptoms.
There are no reviews that match your criteria.